Blockbuster cancer drug Keytruda out of reach for most Indian cancer patients
One of the world’s best-selling immunotherapies – pembrolizumab – that has emerged over the last several years as a cornerstone of many hard-to-treat cancers – remains out of reach for most cancer patients in India. The recent approval of pembrolizumab for …